Skip to contentZ
Zivo Bioscience, Inc.
Z
ZIVOZivo Bioscience, Inc. Q3 2021 · 10-Q
Revenue$0.00$0.00— vs Q3 2020 Net Income-$1.55M-$1.55MN/M vs Q3 2020 EPS Diluted-$0.21-$0.21N/M vs Q3 2020 Operating Income-$1,673,115N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Zivo Bioscience, Inc. · CIK 1101026 · Engraved from SEC EDGAR
derived
ended Sep 30, 2021 · filed Nov 15, 2021 · 46 d after period end